BioInsights - Market access: evolving commercialization trends and strategies - spotlight

CELL & GENE THERAPY INSIGHTS

Neil Palmer

Guest Editor:

Neil Palmer, President and Principal Consultant at PDCI Market Access

August 2020

Market access: evolving commercialization trends and strategies

Download PDF

Foreword

Under construction: roadmaps for HTA, pricing and reimbursement of cell and gene therapies

Under construction: roadmaps for HTA, pricing and reimbursement of cell and gene therapies

Neil Palmer

3 September 2020

Expert Insight

Challenges and proposed solutions to value assessment and reimbursement of CAR-T therapies in Europe

Challenges and proposed solutions to value assessment and reimbursement of CAR-T therapies in Europe

Clare Hague, Martin Price

Commentary

The heart of market access: opportunities and challenges for cell and gene therapy development for orphan and prevalent cardiovascular diseases

The heart of market access: opportunities and challenges for cell and gene therapy development for orphan and prevalent cardiovascular diseases

23 September 2020

Joint collaborations and future perspectives for gene therapies.

Joint collaborations and future perspectives for gene therapies.

M Dabbous, B Borissov, C Dussart et al.

3 September 2020

Bringing advanced therapies to the clinic: the Swedish National ATMP Consortium (CAMP/SWElife ATMP)

Bringing advanced therapies to the clinic: the Swedish National ATMP Consortium (CAMP/SWElife ATMP)

S Scheding, H Main, P Blomberg

Challenges in the adoption of regenerative medicine therapies, meeting summary

Challenges in the adoption of regenerative medicine therapies, meeting summary

M Chaddah, S McMahon, J Kusena et al.

Innovative payments for innovative therapies: adopting value-based models in the regenerative medicines & advanced therapy sector

Innovative payments for innovative therapies: adopting value-based models in the regenerative medicines & advanced therapy sector

Janet Lynch Lambert

Interview

How should health technology assessment of ATMPs evolve in Europe?

How should health technology assessment of ATMPs evolve in Europe?

Mondher Toumi

2 September 2020

From rare monogenic diseases to Parkinson’s: market access considerations for gene therapy across large and small indications

From rare monogenic diseases to Parkinson’s: market access considerations for gene therapy across large and small indications

Parag Meswani

HTA evolution in Canada: considerations for cell and gene therapy

HTA evolution in Canada: considerations for cell and gene therapy

Suzanne McGurn